Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
Status:
Not yet recruiting
Trial end date:
2023-07-17
Target enrollment:
Participant gender:
Summary
This study will be a single center, open-label study of a single concentration of ANR- 001.1.
The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7
days.
Phase:
Phase 1
Details
Lead Sponsor:
Aneira Pharma, Inc.
Collaborator:
DataPharm Australia, CMAX Clinical Research, Agilex Australia